EGFR and non-small cell lung carcinoma: Perhaps the best model for EGFR mutation-driven tumorigenesis is in non-small cell lung cancer where activating mutations within exons 18-21 of EGFR have been reported and predict for response to EGFR inhibitors [16,17].